Developing phytoestrogens for breast cancer prevention

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1306-1313

  Liu, Mandy M ^a   Huang, Ying ^a   Wang, Jeffrey ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Chemoprevention; Coumestrol; Daidzein; Enterodiol; Enterolactone; Equol; Estrogen receptor modulator; Genistein; Glycitein; Matairesinol; Phytoestrogens; Resveratrol; Secoisolariciresinol; Sesamin

Indexed keywords

AROMATASE; BIOCHANIN A; COUMESTROL; CYCLIN D1; DAIDZEIN; ENTERODIOL; ENTEROLACTONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FORMONONETIN; GENISTEIN; GLYCITEIN; ISOFLAVONE DERIVATIVE; LIGNAN; MATAIRESINOL; PHYTOESTROGEN; PROTEIN BCL XL; RESVERATROL; SECOISOLARICIRESINOL; STILBENE DERIVATIVE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG USE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MOLECULAR STRUCTURE; PHYTOESTROGENS;

EID: 84870218113     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803833062     Document Type: Article

References (89)

1. A.; Center M. M.; De Santis, C.; Ward, E. M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev., 2010, 19 (8), 1893-1907.
2. Humphrey, L. L.; Helfand, M.; Chan, B. K.; Woolf, S. H. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med., 2002, 137 (5 Part 1), 347-360.
3. Currier, N.; Solomon, S. E.; Demicco, E. G.; Chang, D. L.; Farago, M.; Ying, H.; Dominguez, I.; Sonenshein, G. E.; Cardiff, R. D.; Xiao, Z. X.; Sherr, D. H.; Seldin, D. C. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol. Pathol., 2005, 33 (6), 726-737.
4. McPherson, K.; Steel, C. M.; Dixon, J. M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ, 2000, 321 (7261), 624-628.
5. Yager, J. D.; Davidson, N. E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med., 2006, 354 (3), 270-282.
6. Thomsen, A.; Kolesar, J. M. Chemoprevention of breast cancer. Am. J. Health Syst. Pharm., 2008, 65 (23), 2221-2228.
7. Mishra, P.; Kale, R. K.; Kar, A. Chemoprevention of mammary tumorigenesis and chemomodulation of the antioxidative enzymes and peroxidative damage in prepubertal Sprague Dawley rats by Biochanin A. Mol. Cell. Biochem., 2008, 312 (1-2), 1-9.
8. Serrano, D.; Lazzeroni, M.; Decensi, A. Chemoprevention of colorectal cancer: an update. Tech. Coloproctol., 2004, 8 Suppl 2, s248-252.
9. Hershman, D.; Sundararajan, V.; Jacobson, J. S.; Heitjan, D. F.; Neugut, A. I.; Grann, V. R. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a costeffectiveness analysis. J. Clin. Oncol., 2002, 20 (1), 9-16.
10. Cuzick, J.; Powles, T.; Veronesi, U.; Forbes, J.; Edwards, R.; Ashley, S.; Boyle, P. Overview of the main outcomes in breastcancer prevention trials. Lancet, 2003, 361 (9354), 296-300.
11. Yu, F. L.; Bender, W. A proposed mechanism of tamoxifen in breast cancer prevention. Cancer Detect. Prev, 2002, 26 (5), 370-375.
12. Xing, B.; Huang, X.; Wang, Y. [The effect of long-term tamoxifen therapy on the occurrence of contralateral primary breast cancer]. Chin. J. Oncol., 1996, 18 (2), 143-145.
13. Brauch, H. B.; Schroth, W.; Ingle, J. N.; Goetz, M. P. CYP2D6 and tamoxifen: awaiting the denouement. J. Clin. Oncol., 2011, 29 (34), 4589-4590; author reply 4590-4581.
14. Sporn, M. B.; Dowsett, S. A.; Mershon, J.; Bryant, H. U. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin. Ther., 2004, 26 (6), 830-840.
15. Veronesi, U.; De Palo, G.; Marubini, E.; Costa, A.; Formelli, F.; Mariani, L.; Decensi, A.; Camerini, T.; Del Turco, M. R.; Di Mauro, M. G.; Muraca, M. G.; Del Vecchio, M.; Pinto, C.; D'Aiuto, G.; Boni, C.; Campa, T.; Magni, A.; Miceli, R.; Perloff, M.; Malone, W. F.; Sporn, M. B. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 1999, 91 (21), 1847-1856.
16. Adlercreutz, H. Phytoestrogens and breast cancer. J. Steroid Biochem. Mol. Biol., 2002, 83 (1-5), 113-118.
17. Adlercreutz, H. Epidemiology of phytoestrogens. Baillieres Clin. Endocrinol. Metab., 1998, 12 (4), 605-623.
18. Knight, D. C.; Eden, J. A. Phytoestrogens--a short review. Maturitas, 1995, 22 (3), 167-175.
19. Mense, S. M.; Hei, T. K.; Ganju, R. K.; Bhat, H. K. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ. Health Perspect., 2008, 116 (4), 426-433.
20. Willett, W. C.; Hunter, D. J.; Stampfer, M. J.; Colditz, G.; Manson, J. E.; Spiegelman, D.; Rosner, B.; Hennekens, C. H.; Speizer, F. E. Dietary fat and fiber in relation to risk of breast cancer. An 8-year follow-up. JAMA, 1992, 268 (15), 2037-2044.
21. Velentzis, L. S.; Woodside, J. V.; Cantwell, M. M.; Leathem, A. J.; Keshtgar, M. R. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur. J. Cancer, 2008, 44 (13), 1799-1806.
22. Cohen, I.; Tagliaferri, M.; Tripathy, D. Traditional Chinese medicine in the treatment of breast cancer. Semin. Oncol., 2002, 29 (6), 563-574.
23. Wu, A. H.; Yu, M. C.; Tseng, C. C.; Twaddle, N. C.; Doerge, D. R. Plasma isoflavone levels versus self-reported soy isoflavone levels in Asian-American women in Los Angeles County. Carcinogenesis, 2004, 25 (1), 77-81.
24. Fremont, L. Biological effects of resveratrol. Life Sci., 2000, 66 (8), 663-673.
25. Jung, W.; Yu, O.; Lau, S. M.; O'Keefe, D. P.; Odell, J.; Fader, G.; McGonigle, B. Identification and expression of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes. Nat. Biotechnol., 2000, 18 (2), 208-212.
26. Kuhnle, G. G.; Dell'Aquila, C.; Aspinall, S. M.; Runswick, S. A.; Mulligan, A. A.; Bingham, S. A. Phytoestrogen content of foods of animal origin: dairy products, eggs, meat, fish, and seafood. J. Agric. Food Chem., 2008, 56 (21), 10099-10104.
27. Cassidy, A.; Albertazzi, P.; Lise Nielsen, I.; Hall, W.; Williamson, G.; Tetens, I.; Atkins, S.; Cross, H.; Manios, Y.; Wolk, A.; Steiner, C.; Branca, F. Critical review of health effects of soyabean phytooestrogens in post-menopausal women. Proc. Nutr.Soc., 2006, 65 (1), 76-92.
28. Buck, K.; Zaineddin, A. K.; Vrieling, A.; Linseisen, J.; Chang-Claude, J. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am. J. Clin. Nutr., 2010, 92 (1), 141-153.
29. Lee, H. P.; Gourley, L.; Duffy, S. W.; Esteve, J.; Lee, J.; Day, N. E. Dietary effects on breast-cancer risk in Singapore. Lancet, 1991, 337 (8751), 1197-1200.
30. Lampe, J. W.; Nishino, Y.; Ray, R. M.; Wu, C.; Li, W.; Lin, M. G.; Gao, D. L.; Hu, Y.; Shannon, J.; Stalsberg, H.; Porter, P. L.; Frankenfeld, C. L.; Wahala, K.; Thomas, D. B. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol. Biomarkers Prev., 2007, 16 (12), 2579-2586.
31. Olsen, A.; Knudsen, K. E.; Thomsen, B. L.; Loft, S.; Stripp, C.; Overvad, K.; Moller, S.; Tjonneland, A. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol. Biomarkers Prev., 2004, 13 (12), 2084-2089.
32. Hedelin, M.; Lof, M.; Olsson, M.; Adlercreutz, H.; Sandin, S.; Weiderpass, E. Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast tumors in Swedish women. J. Nutr., 2008, 138 (5), 938-945.
33. Kuhnle, G. G.; Dell'aquila, C.; Aspinall, S. M.; Runswick, S. A.; Mulligan, A. A.; Bingham, S. A. Phytoestrogen content of cereals and cereal-based foods consumed in the UK. Nutr. Cancer, 2009, 61 (3), 302-309.
34. Li, M.; Poon, P.; Woo, J. A pilot study of phytoestrogen content of soy foods and traditional Chinese medicines for women's health in Hong Kong. Int. J. Food Sci. Nutr., 2004, 55 (3), 201-205.
35. Erdman, J. W., Jr.; Badger, T. M.; Lampe, J. W.; Setchell, K. D.; Messina, M. Not all soy products are created equal: caution needed in interpretation of research results. J. Nutr., 2004, 134 (5), 1229S-1233S.
36. El-Halawany, A. M.; Chung, M. H.; Abdallah, H. M.; Nishihara, T.; Hattori, M. Estrogenic activity of a naringinase-treated extract of Sophora japonica cultivated in Egypt. Pharm. Biol., 2010, 48 (2), 177-181.
37. Rong, H.; Stevens, J. F.; Deinzer, M. L.; Cooman, L. D.; Keukeleire, D. D. Identification of isoflavones in the roots of Pueraria lobata. Planta Med., 1998, 64 (7), 620-627.
38. Kang, S. C.; Lee, C. M.; Choi, H.; Lee, J. H.; Oh, J. S.; Kwak, J. H.; Zee, O. P. Evaluation of oriental medicinal herbs for estrogenic and antiproliferative activities. Phytother. Res., 2006, 20 (11), 1017-1019.
39. Kang, X.; Jin, S.; Zhang, Q. Antitumor and antiangiogenic activity of soy phytoestrogen on 7,12-dimethylbenz[alpha]anthraceneinduced mammary tumors following ovariectomy in Sprague-Dawley rats. J. Food Sci., 2009, 74 (7), H237-242.
40. Cornwell, T.; Cohick, W.; Raskin, I. Dietary phytoestrogens and health. Phytochemistry, 2004, 65 (8), 995-1016.
41. Adlercreutz, H.; Bannwart, C.; Wahala, K.; Makela, T.; Brunow, G.; Hase, T.; Arosemena, P. J.; Kellis, J. T., Jr.; Vickery, L. E. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J. Steroid Biochem. Mol. Biol., 1993, 44 (2), 147-153.
42. Lampe, J. W.; Gustafson, D. R.; Hutchins, A. M.; Martini, M. C.; Li, S.; Wahala, K.; Grandits, G. A.; Potter, J. D.; Slavin, J. L. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol. Biomarkers Prev., 1999, 8 (8), 699-707.
43. Ingram, D.; Sanders, K.; Kolybaba, M.; Lopez, D. Case-control study of phyto-oestrogens and breast cancer. Lancet, 1997, 350 (9083), 990-994.
44. Saarinen, N. M.; Huovinen, R.; Warri, A.; Makela, S. I.; Valentin-Blasini, L.; Sjoholm, R.; Ammala, J.; Lehtila, R.; Eckerman, C.; Collan, Y. U.; Santti, R. S. Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol. Cancer Ther., 2002, 1 (10), 869-876.
45. Saarinen, N. M.; Warri, A.; Dings, R. P.; Airio, M.; Smeds, A. I.; Makela, S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int. J. Cancer, 2008, 123 (5), 1196-1204.
46. Figueiras, T. S.; Neves-Petersen, M. T.; Petersen, S. B. Activation Energy of Light Induced Isomerization of Resveratrol. J. Fluoresc., 2011, 21(5),1897-1906.
47. Wang, S. Y.; Chen, C. T.; Wang, C. Y.; Chen, P. Resveratrol content in strawberry fruit is affected by preharvest conditions. J. Agric. Food Chem., 2007, 55 (20), 8269-8274.
48. Sobolev, V. S.; Cole, R. J. Trans-resveratrol content in commercial peanuts and peanut products. J. Agric. Food Chem., 1999, 47 (4), 1435-1439.
49. Lyons, M. M.; Yu, C.; Toma, R. B.; Cho, S. Y.; Reiboldt, W.; Lee, J.; van Breemen, R. B. Resveratrol in raw and baked blueberries and bilberries. J. Agric. Food Chem., 2003, 51 (20), 5867-5870.
50. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E., Jr.; Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32 (12), 1377-1382.
51. Almeida, L.; Vaz-da-Silva, M.; Falcao, A.; Soares, E.; Costa, R.; Loureiro, A. I.; Fernandes-Lopes, C.; Rocha, J. F.; Nunes, T.; Wright, L.; Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res., 2009, 53 Suppl 1, S7-15.
52. Goswami, S. K.; Das, D. K. Resveratrol and chemoprevention. Cancer Lett., 2009, 284 (1), 1-6.
53. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B. B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62 (17), 4945-4954.
54. Turner, J. V.; Agatonovic-Kustrin, S.; Glass, B. D. Molecular aspects of phytoestrogen selective binding at estrogen receptors. J. Pharm. Sci., 2007, 96 (8), 1879-1885.
55. Nilsson, S.; Gustafsson, J. A. Estrogen receptors: therapies targeted to receptor subtypes. Clin. Pharmacol. Ther., 2011, 89 (1), 44-55.
56. Chantzi, N. I.; Meligova, A. K.; Dhimolea, E.; Petrou, C. C.; Mitsiou, D. J.; Magafa, V.; Pechtelidou, A.; Florentin, I.; Kitraki, E.; Cordopatis, P.; Tiniakos, D. G.; Alexis, M. N. Insights into ectopic estrogen receptor expression, nucleocytoplasmic distribution and interaction with chromatin obtained with new antibodies to estrogen receptors alpha and beta. Steroids, 2011, 76 (10-11), 974-985.
57. Younes, M.; Honma, N. Estrogen receptor beta. Arch. Pathol. Lab Med., 2011, 135 (1), 63-66.
58. Mueller, S. O.; Simon, S.; Chae, K.; Metzler, M.; Korach, K. S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci., 2004, 80 (1), 14-25.
59. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 1997, 138 (3), 863-870.
60. Cappelletti, V.; Miodini, P.; Di Fronzo, G.; Daidone, M. G. Modulation of estrogen receptor-beta isoforms by phytoestrogens in breast cancer cells. Int. J. Oncol., 2006, 28 (5), 1185-1191.
61. Paruthiyil, S.; Cvoro, A.; Zhao, X.; Wu, Z.; Sui, Y.; Staub, R. E.; Baggett, S.; Herber, C. B.; Griffin, C.; Tagliaferri, M.; Harris, H. A.; Cohen, I.; Bjeldanes, L. F.; Speed, T. P.; Schaufele, F.; Leitman, D. C. Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS One, 2009, 4 (7), e6271.
62. Mersereau, J. E.; Levy, N.; Staub, R. E.; Baggett, S.; Zogovic, T.; Chow, S.; Ricke, W. A.; Tagliaferri, M.; Cohen, I.; Bjeldanes, L. F.; Leitman, D. C. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol. Cell. Endocrinol., 2008, 283 (1-2), 49-57.
63. Vivar, O. I.; Saunier, E. F.; Leitman, D. C.; Firestone, G. L.; Bjeldanes, L. F. Selective activation of estrogen receptor-beta target genes by 3,3'-diindolylmethane. Endocrinology, 2010, 151 (4), 1662-1667.
64. Fan, G. W.; Gao, X. M.; Wang, H.; Zhu, Y.; Zhang, J.; Hu, L. M.; Su, Y. F.; Kang, L. Y.; Zhang, B. L. The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J. Steroid Biochem. Mol. Biol., 2009, 113 (3-5), 275-280.
65. Yue, W.; Berstein, L. M.; Wang, J. P.; Clark, G. M.; Hamilton, C. J.; Demers, L. M.; Santen, R. J. The potential role of estrogen in aromatase regulation in the breast. J. Steroid Biochem. Mol. Biol., 2001, 79 (1-5), 157-164.
66. Almstrup, K.; Fernandez, M. F.; Petersen, J. H.; Olea, N.; Skakkebaek, N. E.; Leffers, H. Dual effects of phytoestrogens result in u-shaped dose-response curves. Environ. Health Perspect., 2002, 110 (8), 743-748.
67. Wang, Y.; Ye, L.; Leung, L. K. A positive feedback pathway of estrogen biosynthesis in breast cancer cells is contained by resveratrol. Toxicology, 2008, 248 (2-3), 130-135.
68. Eng, E. T.; Williams, D.; Mandava, U.; Kirma, N.; Tekmal, R. R.; Chen, S. Suppression of aromatase (estrogen synthetase) by red wine phytochemicals. Breast Cancer Res. Treat, 2001, 67 (2), 133-146.
69. Constantinou, A. I.; Kamath, N.; Murley, J. S. Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Eur. J. Cancer, 1998, 34 (12), 1927-1934.
70. Chen, W. F.; Huang, M. H.; Tzang, C. H.; Yang, M.; Wong, M. S. Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim. Biophys. Acta, 2003, 1638 (2), 187-196.
71. Seo, H. S.; Ju, J. H.; Jang, K.; Shin, I. Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phosphop53 and p21 in normal and malignant estrogen receptor alphanegative breast cells. Nutr. Res., 2011, 31 (2), 139-146.
72. Yin, F.; Giuliano, A. E.; Law, R. E.; Van Herle, A. J. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin- CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res., 2001, 21 (1A), 413-420.
73. Choi, E. J.; Kim, G. H. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB- 453 cells. Phytomedicine, 2008, 15 (9), 683-690.
74. Yu, X. P.; Mi, M. T.; Zhu, J. D. [Effect of genistein on expression of angiogenesis related factors in HER-2/neu-overexpressing breast cancer cells]. Shi Yan Sheng Wu Xue Bao, 2004, 37 (3), 251-253.
75. Harikumar, K. B.; Sung, B.; Tharakan, S. T.; Pandey, M. K.; Joy, B.; Guha, S.; Krishnan, S.; Aggarwal, B. B. Sesamin manifests chemopreventive effects through the suppression of NF-kappa Bregulated cell survival, proliferation, invasion, and angiogenic gene products. Mol. Cancer Res., 2010, 8 (5), 751-761.
76. Saarinen, N. M.; Abrahamsson, A.; Dabrosin, C. Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int. J. Cancer, 2010, 127 (3), 737-745.
77. Piller, R.; Chang-Claude, J.; Linseisen, J. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur. J. Cancer Prev., 2006, 15 (3), 225-232.
78. Vandenplas, Y.; De Greef, E.; Devreker, T.; Hauser, B. Soy infant formula: is it that bad? Acta Paediatr., 2011, 100 (2), 162-166.
79. Sahin, G.; Aydin, A.; Isimer, A.; Ozalp, I.; Duru, S. Aluminum content of infant formulas used in Turkey. Biol. Trace Elem. Res., 1995, 50 (1), 87-96.
80. Todaka, E.; Sakurai, K.; Fukata, H.; Miyagawa, H.; Uzuki, M.; Omori, M.; Osada, H.; Ikezuki, Y.; Tsutsumi, O.; Iguchi, T.; Mori, C. Fetal exposure to phytoestrogens--the difference in phytoestrogen status between mother and fetus. Environ Res., 2005, 99 (2), 195-203.
81. Jefferson, W. N.; Padilla-Banks, E.; Newbold, R. R. Adverse effects on female development and reproduction in CD-1 mice following neonatal exposure to the phytoestrogen genistein at environmentally relevant doses. Biol. Reprod., 2005, 73 (4), 798-806.
82. Nobert, G. S.; Kraak, M. M.; Crawford, S. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches. Bull Cancer, 2006, 93 (7), E59-66.
83. Satih, S.; Chalabi, N.; Rabiau, N.; Bosviel, R.; Fontana, L.; Bignon, Y. J.; Bernard-Gallon, D. J. Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach. OMICS, 2010, 14 (3), 231-238.
84. Branca, F.; Lorenzetti, S. Health effects of phytoestrogens. Forum Nutr., 2005, 57, 100-111.
85. Kennedy, A. R. The evidence for soybean products as cancer preventive agents. J. Nutr., 1995, 125 (3 Suppl), 733S-743S.
86. Santell, R. C.; Kieu, N.; Helferich, W. G. Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. J. Nutr., 2000, 130 (7), 1665-1669.
87. King, R. A.; Bursill, D. B. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am. J. Clin. Nutr., 1998, 67 (5), 867-872.
88. Anupongsanugool, E.; Teekachunhatean, S.; Rojanasthien, N.; Pongsatha, S.; Sangdee, C. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal. BMC Clin. Pharmacol., 2005, 5 (1), 2.
89. Joshi, J. V.; Vaidya, R. A.; Pandey, S. N.; Agashe, S.; Chandrasekharan, S.; Menon, S. K.; Vaidya, A. D. Plasma levels of genistein following a single dose of soy extract capsule in Indian women. Indian J. Med. Res., 2007, 125 (4), 534-541.